PR84951

NETANYA, Israel, July 30, 2020, /PRNewswire=KYODO JBN/--

Trobix Innovation Ltd. (Trobix Bio [https://www.trobixbio.com/ ]), an

Israeli-based biotechnology company developing therapies to remove the threat

of antimicrobial resistance, announces the closing of a US $ 3 Million Series A

funding from its lead investor, Chartered Opus [https://chartered-opus.com/en/

]. The funding will be used to advance the company's antimicrobial resistance

platform technology and to further the pre-clinical development of the its lead

product, TBX101.

"I am grateful to Chartered Opus for their confidence in our technology and

their trust in our team", said Dr. Adi Elkeles, Founder & CEO of Trobix Bio.

"Antimicrobial resistant threatens to undermine the achievements of modern

medicine, and Trobix Bio is committed to developing products that can

effectively tackle this imminent threat", he added.

"The Covid-19 pandemic stresses the urgent need to tackle the global challenges

of infectious diseases, and the global need for a solution to the threat of

antimicrobial resistance was there from day one", says Eyal Agmoni, Chairman of

Chartered Group. "Trobix Bio is set to revolutionize the landscape of

phage-based nanomedicine by introducing its game-changing, precision particle

disruptive technology. We are very happy with the progress made by the team and

are glad to be part of this unique venture".

About Trobix Bio

Trobix Bio is a preclinical biotechnology company, developing therapies to

remove the threat of antimicrobial resistance, a global crisis strongly

evidenced nowadays during the COVID-19 Pandemic. Trobix Bio leverages its

ActiSense™ and GoTrap™ technologies to develop phage-based products that can

effectively deliver DNA to a wide range of bacterial pathogens, and actively

sensitize these pathogens to antibiotics. The company's lead product, TBX101,

aims to treat patients carrying gut antimicrobial resistant bacteria, resulting

in an antibiotic sensitive gut microbiome. Trobix Bio's precision medicine

technology minimizes resistance development to TBX101.

About Chartered Opus

Chartered Opus is a production platform for investment products combining

structural and technological innovations to a new methodology in Structured

Products. Opus is the preferred investment vehicle for the Chartered Group

[http://www.charteredgroup.com/ ] High-Tech division. In the past two years,

Chartered group grew its high-tech portfolio to about 30 companies all with

disruptive technologies, including being the anchor investor for TAU Ventures

at Tel Aviv University.  

Logo - https://mma.prnewswire.com/media/1221167/Trobix_Chartered_Opus_Logo.jpg

For more information, please contact:  

Dr. Adi Elkeles

CEO & co-Founder  

Trobix Bio

Email: adie@trobixbio.com

SOURCE: Trobix Innovation Ltd